Skip to main content
OpenTrials
Completed

NCT Number: NCT05369221

Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space

In this study, 5 subjects will be enrolled and the cumulative D2cc dose for rectum during brachytherapy will be recorded as the primary outcome measures.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a phase I prospective study of 5 patients to determine if PEG hydrogel (ReSpace™) reduces the radiation dose delivered to the rectum during radiation therapy for cervical cancer by increasing the space between the cervix and the anterior rectal wall. In the other word, the purpose of this study is to assess whether the use of ReSpace™ hydrogel results in a reduction of radiation exposure to the anterior rectum.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with pathologically confirmed cervical cancer who must be scheduled to undergo radical radiotherapy by means of intensity-modulated radiotherapy combined with 3D brachytherapy.
  • Karnofsky score ≥ 70.
  • Subjects aged ≥ 18 years and ≤ 75 years.
  • Subjects must be able to cooperate in completing the entire study.
  • The subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate MRI.
  • No contraindications to CT scanning.
  • Subjects must be able to understand the purpose of the trial, voluntarily participate and sign an informed consent form.

Exclusion criteria

  • Subjects who have received prior pelvic radiotherapy.
  • Subjects whose target tumors have been previously treated (chemotherapy, immunotherapy, surgical treatment, etc.)
  • Subjects with other primary malignancies
  • Subjects with contraindications to radiotherapy, as determined by the investigators
  • Subjects with injection site infections.
  • Subjects who are allergic to the ingredients of the device.
  • Subjects whose tumors invade the injection site and affect the injection process and injection safety, as determined by the investigators
  • Persons with severe mental illness, cognitive impairment and thinking disorders.
  • Participants in other drug clinical trials or medical device clinical trials 1 month prior to screening
  • Pregnant or lactating women or those who plan to get pregnant within the last six months
  • Subjects who cannot be followed up as prescribed by the doctor
  • Other conditions that, in the judgment of the investigator, make the subject unsuitable for enrollment

Treatment and study plan

ReSpace™

Device

All of the subjects will be injected with ReSpace™ hydrogel.

Primary outcomes

  1. The cumulative D2cc dose for rectum during brachytherapy

    Time frame: 21 days post index procedure

    The mean of the cumulative rectum D2cc dose during brachytherapy will be calculated for subjects. which will be used to validate the parameter selection for phase II sample size estimation.

Secondary outcomes

  1. Implantation success rate of hydrogel spacer

    Time frame: during procedure

    The success rate of hydrogel spacer implantation will be evaluated by the investigator for subjects.

  2. Evaluation of device performance of hydrogel spacer

    Time frame: during procedure

    The ease of use of the test device will be evaluated by the investigator on the day of Operation. The evaluation items are as follows:

    • Whether the device is easy to assemble.
    • Whether the process of positioning the needle is smooth and whether it is easy to position the needle.
    • Whether the device is easy to inject and whether the injection process is smooth.
  3. Injection volume of hydrogel spacer

    Time frame: during procedure

    Recording the amount of hydrogel spacer injected in the subjects,which will be used to evaluate the reasonableness of the injected dose of ReSpace™ when hydrogel is injected between the rectum and cervix in women undergoing radiation therapy.

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Collaborators

  • Shanghai Reunion Biotech Co.,Ltd.

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 11, 2022
Registry last updated
Nov 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.